These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18049060)

  • 1. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
    Szetela AB; Gibson DE
    Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
    Marsé H; Van Cutsem E; Grothey A; Valverde S
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S16-30. PubMed ID: 15341879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of capecitabine (Xeloda) for cancer nursing practice.
    Gerbrecht BM; Kangas T
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S63-71. PubMed ID: 15341883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    Sternberg CN; Reichardt P; Holland M
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nursing considerations for capecitabine-based combination therapy.
    Becze E
    ONS Connect; 2009 Apr; 24(4):14-5. PubMed ID: 19413236
    [No Abstract]   [Full Text] [Related]  

  • 6. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
    Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.
    Barrett-Lee P; Bidard FC; Pierga JY
    Cancer Treat Rev; 2009 Nov; 35(7):582-9. PubMed ID: 19632050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral capecitabine (Xeloda) in cancer treatment.
    Doyle DP; Engelking C
    Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
    [No Abstract]   [Full Text] [Related]  

  • 9. Positive results achieved with new oral chemotherapy agent.
    Timmerman D
    Oncol Nurs Forum; 1999 May; 26(4):675. PubMed ID: 10337634
    [No Abstract]   [Full Text] [Related]  

  • 10. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
    Twelves CJ
    Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
    Law CC; Fu YT; Chau KK; Choy TS; So PF; Wong KH
    Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine-based combination therapy for breast cancer: implications for nurses.
    Frye DK
    Oncol Nurs Forum; 2009 Jan; 36(1):105-13. PubMed ID: 19136344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine: a new adjuvant option for colorectal cancer.
    Berg DT
    Clin J Oncol Nurs; 2006 Aug; 10(4):479-86. PubMed ID: 16927901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine: nursing implications of a new oral chemotherapeutic agent.
    Mrozek-Orlowski ME; Frye DK; Sanborn HM
    Oncol Nurs Forum; 1999 May; 26(4):753-62. PubMed ID: 10337653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
    Scarabelli L; Giovanardi F; Gervasi E; Prati G; Pezzuolo D; Scaltriti L
    Chemotherapy; 2013; 59(5):369-72. PubMed ID: 24821441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine: an overview of the side effects and their management.
    Saif MW; Katirtzoglou NA; Syrigos KN
    Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
    Faithfull S; Deery P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S54-62. PubMed ID: 15341882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.